The Dengjel and De Virgilio Labs at the Dept. of Biology, University of Fribourg are interested in cellular
signal transduction and protein homeostasis. We characterize molecular pathways critical for cell
homeostasis, autophagy regulation and autophagosome biogenesis and employ mammalian and/or yeast
cell culture models, protein biochemistry, and mass spectrometry-based proteomics (1-4). Current projects
are supported by third-party grants from the Swiss National Science Foundation and private foundations.
We look for highly motivated PhD students with interests in the areas outlined above. Excellent
communication skills in English are of benefit.

We offer:
• a stimulating, interdisciplinary scientific environment
• state-of-the-art central facilities for proteomic, imaging and bioinformatic analyses
• a coordinated graduate program (https://www.unifr.ch/bio/en/studies/graduate-school-fglm/)
• a competitive Swiss salary

Fribourg and its University are located in the heart of Switzerland, 30 min from Bern and 50 min from
Lausanne. Research and life conditions are excellent. Major facilities are either on campus or available
through national networks. The Dengjel Lab is actively engaged in SKINTEGRITY.CH and Life Science
Switzerland (LS²).

The starting date for this position is July 1st, 2024 (or later). Interested candidates should send a SINGLE
PDF application including a CV, a brief statement of their research interests, a copy of their MSc diploma,
and names of three referees by email to: stephanie.kaeser-pebernard@unifr.ch

Der Rektor verantwortet die Lehre an der ETH Zürich. Er legt seine Abteilung «Lehrtechnologie- und -entwicklung» mit seinem Stabsbereich «Strategische Initiativen» zu einer neuen Abteilung zusammen, die ihm direkt unterstellt ist. Ihre Bezeichnung steht noch nicht fest. Sie ist die zentrale Einheit zur Unterstützung aller an der Lehre beteiligter Personen in Fragen rund um die Entwicklung ihrer Lehr- und Lernformen, der Curricula und der in der Lehre verwendeten Technologien. Zudem setzt die Abteilung grosse, ETH-weite Projekte um. Diese dienen der Weiterentwicklung der Lehre, der Komplettierung der Lernerfahrung der Studierenden und der Unterstützung der langfristigen strategischen Ausrichtung der Lehre.

Stellenbeschreibung
In dieser Funktion führen Sie die beiden bisher getrennten Einheiten zusammen. Sie sind für die fachliche, personelle und organisatorische Führung und Ausrichtung der Abteilung verantwortlich. Zu Ihren Geschäften gehören die Umsetzung von Lehrprojekten, wie z.B. die Förderung projektbasierter Lehre oder die Begleitung der Curriculumsentwicklungen der Departemente der ETH. Sie pflegen die Zusammenarbeit mit dem Netzwerk der Lehrspezialistinnen und Lehrspezialisten an den Departementen. Sie arbeiten eng mit dem Rektor und dem Prorektor Curriculumsentwicklung zusammen und setzen mit ihnen eine gemeinsame Strategie für den Lehrbereich um. 

https://jobs.ethz.ch/job/view/JOPG_ethz_m6Zh62nPnB15CQECbN

WHO WE ARE

Disco Pharmaceuticals is a young ETH spin-off company based in Zurich/Switzerland and Cologne/Germany.
We leverage a novel mass spectrometric technology to investigate processes that are fundamental to
cancer biology. We combine methodologies in cell biology, biochemistry, mass spectrometry with
computational tools to identify proteins selectively expressed on cancer cells. Our ultimate goal is to
develop innovative therapies for cancers with high unmet clinical need.

POSITION

To strengthen our activities, DISCO Pharmaceuticals is looking for a talented full-time research associate to
join our international team. The successful candidate will be based in Zurich and work with a dynamic and
highly motivated team to drive the development of novel antibody therapeutics for indications with high
unmet medical needs. Given the nature of the duties and responsibilities, this in a mostly on-site role.

CONTACT

For further information and to apply, please contact Emanuela Milani, emanuela@discopharma.de

More information in pdf.

WHO WE ARE

Disco Pharmaceuticals is a young ETH spin-off company based in Zurich/Switzerland and Cologne/Germany. We leverage a novel mass spectrometric technology to investigate processes that are fundamental to cancer biology. We combine methodologies in cell biology, biochemistry, mass spectrometry with computational tools to identify proteins selectively expressed on cancer cells. Our ultimate goal is to develop innovative therapies for cancers with high unmet clinical need.

POSITION

To strengthen our activities, DISCO Pharmaceuticals is looking for an enthusiastic scientist to join our international team. Candidates should have a solid background in protein chemistry and molecular biology, with an interest to apply their skills for development of novel cancer therapies. The successful candidate will be based in Zurich and work with a dynamic and highly motivated team to drive the development of novel antibody therapeutics for indications with high unmet medical need. The candidate will collaborate with colleagues in computational biology, biology and antibody discovery.

CONTACT

For further information and to apply, please contact Emanuela Milani, emanuela@discopharma.de

More information in pdf.